The same study reported that the inhibitor treatment causes a reduction of COX-2, p-ERK, and p-Akt, implicating the Cyclin B1/CDK1 axis and its involvement in other signaling pathways regulating the growth of gastric cancer cells [200]. This evidence concerns the gene CDK1 and gastric cancer.